All In Biotech

Drug Trial Radar · NCT00750282

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

An Open-label, Non-randomized, Multi-center Study to Optimize Image Assessment and Evaluate the Efficacy and Safety of BAY 94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection/Exclusion of Cerebral Amyloid Beta in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

422

Actual

Start

Aug 2008

Primary completion

Nov 2010

Study completion Nov 2010

Sponsor

Lead sponsor
Lantheus Biosciences Ltd.Industry
Sponsor type
Industry
First posted
Sep 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission tomography (PET). IMP binds to amyloidal beta protein accumulating in brain tissue already from early stages of Alzheimer's disease (AD). IMP is therefore a potential tracer to be used for detecting amyloid plaques. For each subject it is required to visit the study centre during the screening phase, on the PET imaging day and for 1 follow-up visit on the next day. A telephone call for safety follow-up will be performed 7 days after IMP administration. During the screening phase the subject's medical, neurological and surgical history, specific laboratory tests related to AD, MRI of the brain and certain neuro-psychiatric tests will be performed. Clinical safety measures (physical examinations, vital signs, electrocardiogram (ECG) and laboratory tests) will be performed on the PET imaging day before IMP injection and monitored during and after two PET imaging sessions. Clinical safety measures will be performed again on the follow-up visit next day. The results of PET imaging with IMP will be compared between probable AD patients and healthy volunteers (HV). The clinical diagnosis is based on international validated and accepted criteria and established after comprehensive clinical and neuro-psychiatric examinations

Conditions

  • Alzheimer Disease
  • Amyloid Beta-Protein

Interventions

  • Florbetaben (BAY94-9172)Drug

    Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of TruthTime frame: 90 - 110 min after investigational medical product (IMP) injection
  2. Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.Time frame: 90 - 110 min after IMP injection

Locations

23 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Sun City, Arizona

  • Site not named

    Stanford, California

  • Site not named

    New Haven, Connecticut

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Providence, Rhode Island

  • Site not named

    Westmead, New South Wales, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Heidelberg, Victoria, Australia

  • Site not named

    Erlangen, Bavaria, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    Essen, North Rhine-Westphalia, Germany

  • Site not named

    Jülich, North Rhine-Westphalia, Germany

  • Site not named

    Münster, North Rhine-Westphalia, Germany

  • Site not named

    Dresden, Saxony, Germany

  • Site not named

    Leipzig, Saxony, Germany

  • Site not named

    Berlin, State of Berlin, Germany

  • Site not named

    Kobe, Hyōgo, Japan

  • Site not named

    Kobe, Hyōgo, Japan

  • Site not named

    Bunkyo-ku, Tokyo, Japan

  • Site not named

    Zurich, Canton of Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.